{"id":2543768,"date":"2023-05-26T12:11:33","date_gmt":"2023-05-26T16:11:33","guid":{"rendered":"https:\/\/platoai.gbaglobal.org\/platowire\/medtronics-fy23-revenue-reaches-31-2-billion\/"},"modified":"2023-05-26T12:11:33","modified_gmt":"2023-05-26T16:11:33","slug":"medtronics-fy23-revenue-reaches-31-2-billion","status":"publish","type":"platowire","link":"https:\/\/platoai.gbaglobal.org\/platowire\/medtronics-fy23-revenue-reaches-31-2-billion\/","title":{"rendered":"Medtronic’s FY23 Revenue Reaches $31.2 Billion"},"content":{"rendered":"

Medtronic, a global leader in medical technology, recently announced its financial results for the fiscal year 2023. The company reported a revenue of $31.2 billion, which is a 5% increase from the previous year. This growth can be attributed to the company’s strong performance in all of its business segments.<\/p>\n

Medtronic’s Cardiac and Vascular Group, which includes products such as pacemakers and stents, reported a revenue of $11.4 billion, a 4% increase from the previous year. The company’s Minimally Invasive Therapies Group, which includes products such as surgical instruments and respiratory devices, reported a revenue of $10.6 billion, a 6% increase from the previous year. The Restorative Therapies Group, which includes products such as spinal cord stimulators and insulin pumps, reported a revenue of $9.2 billion, a 5% increase from the previous year.<\/p>\n

The company’s strong performance can also be attributed to its focus on innovation and research and development. Medtronic invested $2.3 billion in research and development in FY23, which is a 7% increase from the previous year. The company launched several new products during the year, including the MiniMed 780G insulin pump system and the Hugo robotic-assisted surgery system.<\/p>\n

Medtronic’s CEO, Geoff Martha, stated that the company’s strong performance is a result of its commitment to improving patient outcomes and delivering value to its customers. He also stated that the company is well-positioned for future growth, with a strong pipeline of innovative products and a focus on expanding its presence in emerging markets.<\/p>\n

In addition to its financial performance, Medtronic also made significant contributions to society during the year. The company donated over $100 million in cash and product donations to support COVID-19 relief efforts around the world. The company also launched several initiatives to address health disparities and improve access to healthcare in underserved communities.<\/p>\n

Overall, Medtronic’s FY23 revenue of $31.2 billion is a testament to the company’s strong performance and commitment to innovation and improving patient outcomes. With a focus on research and development and expanding its presence in emerging markets, the company is well-positioned for future growth and continued success.<\/p>\n